RCT | Gemcitabine vs. Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer – Nature Communications

Commentary on Twitter

Gemcitabine or nab-paclitaxel in combination with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer: results of a randomized phase 3 trial.https://t.co/RKZYdLRbHq#CancerResearch @natrescancer pic.twitter.com/CrCOCJ2HMu

— Nature Communications (@NatureComms) July 13, 2022